Answers are grounded in this paper and cite their sources.
Glucocorticoid tapering in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis has been accelerated, whereas avacopan offers an alternative despite trial retraction. However, whether these regimens are safely implemented in routine practice remains uncertain. We analysed 774 induction episodes of microscopic polyangiitis or granulomatosis with polyangiitis from the J-CANVAS registry (2017–2023), classifying tapering speed at week 8 according to whether the dose was at or below the PEXIVAS reduced-dose target, with overlap weighting on 15 covariates; the primary outcome was 52-week relapse. The faster-taper group received 1448 mg less cumulative prednisolone over weeks 0–24 than the slower-taper group, with a trend toward a higher risk of relapse (hazard ratio, 1.53; 95% confidence interval, 0.90–2.58) driven by minor relapses. Over weeks 8–24, avacopan spared no more glucocorticoid than faster tapering without the drug (649 versus 691 mg less than slower tapering). Attainment of the week-8 target increased from 14.0% to 43.5%, yet only 15.3% met the standard target by week 20, and the between-centre variation was substantial (median odds ratio, 2.66). Faster tapering has been adopted in routine care and has substantially reduced exposure, with any excess relapse confined to minor events. No increase in major relapses or deaths was detected. Whether the exchange is worthwhile is a clinical judgement.
No takes yet. Share an insight, caveat, or question.
Mori et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: